Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 8/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27786209 | 1.00 | GRM8 (0.52) | GRM8GRM4KMOCYP3A4SMN1; SMN2 | |
| Dinitrophenylene SCHEMBL28977791 | 0.74 | KMO (0.58) | GRM8GRM4KMOGRM6 | |
| SCHEMBL7511838 | 0.73 | GRM8 (0.51) | GRM8GRM4KMOCASRGRM6 | |
| SCHEMBL7511836 | 0.73 | GRM8 (0.51) | GRM8GRM4KMOCASRGRM6 | |
| SCHEMBL9755844 | 0.73 | POLB (0.51) | — | |
| SCHEMBL10591572 | 0.73 | POLB (0.51) | — | |
| Trinitrophenol SCHEMBL3985940 | 0.72 | GRM8 (0.57) | GRM8GRM4GRM6 | |
| Trinitrophenol SCHEMBL3985938 | 0.72 | GRM8 (0.57) | GRM8GRM4GRM6 | |
| SCHEMBL3124322 | 0.72 | GRM8 (0.53) | GRM8GRM4GRM6 | |
| SCHEMBL11591209 | 0.71 | GRM8 (0.50) | GRM8GRM4KMOGRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196428-B2 | Modification of cupredoxin derived peptides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-02-05 | — | — | US | claimed |
| US-20170174729-A1 | MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | claimed |
| EP-2398490-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | Cdg Therapeutics Inc (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100267608-A1 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-21 | — | — | US | claimed |
| WO-2010096681-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | CDG THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20090286719-A1 | MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-19 | — | — | US | claimed |
| EP-2061487-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | The Board of Trustees of the University of Illinois (US) | 2009-05-27 | — | — | EP | claimed |
| WO-2008033820-A2 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-03-20 | — | — | WO | claimed |
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTICS INC (US) | 2024-04-18 | — | — | US | disclosed |
| US-20220017569-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11046733-B2 | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-06-29 | — | — | US | disclosed |
| US-10889621-B2 | Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200172581-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER WITH CpG RICH DNA AND CUPREDOXINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-06-04 | — | — | US | disclosed |
| US-10590177-B2 | Modifications of cupredoxin derived peptides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2007018671-A2 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007012004-A2 | TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN BARRIER AND INTO BRAIN CANCER CELLS, AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006127477-A2 | COMPOSITIONS AND METHODS FOR TREATING MALARIA WITH CUPREDOXIN AND CYTOCHROME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127514-A2 | COMPOSITIONS AND METHODS FOR TREATING HIV INFECTION WITH CUPREDOXIN AND CYTOCHROME C | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060251669-A1 | Compositions and methods for treating malaria with cupredoxin and cytochrome | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-09 | — | — | US | disclosed |
| US-20060251639-A1 | Compositions and methods for treating HIV infection with cupredoxin and cytochrame C | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | VIP, NGLY1, IAPP | GRM8 4136/4885GRM4 3767/4885KMO 4360/4885 |
| US-20220017569-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | VIP, NGLY1, IAPP | GRM8 4136/4885GRM4 3767/4885KMO 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.